Plain-English translation of NCT07851259 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , an injectable medication, can help slow or stop vision loss in people with geographic atrophy—a serious eye condition caused by age-related macular degeneration. Geographic atrophy happens when cells in the back of the eye gradually break down, creating areas of permanent vision loss. This treatment is being studied to see if it can help protect the remaining vision in people living with this condition.
Right now, there are very few treatment options for geographic atrophy, and it continues to cause vision loss over time. This trial exists to find out whether this new medication could offer patients a way to preserve their eyesight and slow the progression of the disease.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication (at one of two different doses) or a placebo injection into your eye. You'll visit the research center multiple times so doctors can monitor your vision, take eye images, and check for any side effects. The study involves comparing how well this treatment works compared to placebo in slowing the progression of geographic atrophy.
AI-generated summary from trial data · Oct 30, 2026 · Not medical advice
United States